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Abstract
Background: Legionnaires’ disease (LD) is associated with high mortality rates and poses a diagnostic and
therapeutic challenge. Use of the rapid urinary antigen test (UAT) has been linked to improved outcome. We
examined the association between the method of diagnosis (UAT or culture) and various clinical and
microbiological characteristics and outcome of LD.
Methods: Consecutive patients with pneumonia and confirmation of Legionella infection by a positive UAT and/or
a positive culture admitted between the years 2006–2012 to a university hospital were retrospectively studied.
Isolated L. pneumophila strains were subject to serogrouping, immunological subtyping and sequence-based typing.
Variables associated with 30-day all-cause mortality were analyzed using logistic regression as well as cox
regression.
Results: Seventy-two patients were eligible for mortality analyses (LD study group), of whom 15.5 % have
died. Diagnosis based on positive L. pneumophila UAT as compared to positive culture (OR = 0.18, 95 % CI
0.03–0.98, p = 0.05) and administration of appropriate antibiotic therapy within 2 hospitalization days as
compared to delayed therapy (OR = 0.16, 95 % CI 0.03–0.90, p = 0.04) were independently associated with
reduced mortality. When controlling for intensive care unit (ICU) admissions, the method of diagnosis became
non-significant. Survival analyses showed a significantly increased death risk for patients admitted to ICU
compared to others (HR 12.90, 95 % CI 2.78–59.86, p = 0.001) and reduced risk for patients receiving
appropriate antibiotic therapy within the first two admissions days compared to delayed therapy (HR 0.13,
95 % CI 0.04–0.05, p = 0.001). Legionella cultures were positive in 35 patients (including 29 patients from the
LD study group), of whom 65.7 % were intubated and 37.1 % have died. Sequence type (ST) ST1 accounted
for 50.0 % of the typed cases and ST1, OLDA/Oxford was the leading phenon (53.8 %). Mortality rate among
patients in the LD study group infected with ST1 was 18.2 % compared to 42.9 % for non-ST1 genotypes
(OR = 0.30, 95 % CI 0.05-1.91, p = 0.23).
Conclusions: The study confirms the importance of early administration of appropriate antibiotic therapy and
at the same time highlights the complex associations of different diagnostic approaches with LD outcome.
Infection with ST1 was not associated with increased mortality. Genotype effects on outcome mandate
examination in larger cohorts.
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Background
Legionella pneumophila, especially serogroup 1 is an im-
portant cause of severe pneumonia which is usually ac-
quired in the community and less commonly during
hospitalization [1, 2]. Legionella pneumonia, also known
as Legionnaires’ disease (LD), is characteristically a dis-
ease of middle age and elderly patients, and may be as-
sociated with a high mortality rate [3, 4]. Possible factors
contributing to adverse outcomes include host suscepti-
bility, appropriateness of therapy and possibly the viru-
lence of infecting strain [5–7].
Legionella spp. are resistant to beta-lactam antibiotics,
which constitute the most commonly prescribed agent
for patients with pneumonia. The recommended treat-
ment for infections due to Legionella spp. includes
macrolides, quinolones and tetracyclines [1]. Hence, ap-
propriate antibiotic therapy may be often delayed, espe-
cially if Legionella is not a priori considered the etiologic
agent. Another obstacle for the timely administration of
appropriate therapy is delayed diagnosis. Respiratory
culture-based diagnosis, the gold standard for diagnosis,
requires specialized media and expertise, has a long
turnaround time (7-14 days), and is not routinely per-
formed in many clinical laboratories [8]. Serologic studies
mostly require paired samples obtained two weeks apart
[8] and largely have been abondoned in recent years.
The introduction of the urinary antigen tests (UAT)
for detection of L. pneumophila serogroup 1, the most
common etiologic agent of LD, has revolutionized LD
diagnosis. In the US, between the years 2000–2009 UAT
was used to confirm LD diagnosis in 97 % of cases, cul-
ture in 5 % and serology or direct fluorescent antigen
testing in <1 % [9]. Similarly in Europe the average de-
tection rate by UAT was 79 % and 10 % by culture [10].
UAT allows rapid and timely diagnosis and has been
linked to decreasing mortality trends in the US [2]. The
sensitivity of the current tests for L. pneumophila ser-
ogroup 1 is in the range of 70-90 % with high specificity
(95–100 %) [8]. Some tests are able to detect other sero-
types with lower sensitivity [8]. While being rapid and
readily available in many laboratories, the increasing de-
pendency on UAT for diagnosis of LD may result in sub-
stantial under-detection rate reaching up to 40 % of
cases [8, 11]. Lower rates of culture-based diagnoses
may limit our ability to study the full scope of LD epi-
demiology, perform outbreak investigation and study the
possible impact of L. pneumophila phenotype (particu-
larly non-1 serogroups) or genotype and various clinical
variables on LD. [2, 8, 12]. The rapidly evolving molecu-
lar diagnostic methods are increasingly used for LD
diagnosis but still are less informative than culture-
based methods [13].
LD is a challenge to public health authorities world-
wide [14]. The incidence in the US is on the rise and has
reached 1.15 per 100,000 population in 2009 [9]. In EU
countries the incidence has been stable in recent years.
The overall notification rate in 2012 was 1.1 per 100 000
inhabitants with an associated 10 % case fatality rate
[15]. In Israel, Legionella infection is an important, al-
though uncommon cause of community-acquired and
nosocomial pneumonia [16–18]. In a recent national
surveillance study the reported incidence was 0.5 to 0.9
cases per 100,000 population, corresponding to 38–63
annual case. The case fatality rate was 12.3 % [18]. The
vast majority of cases (88 %) were documented by UAT,
and only 7 % by culture [18].
In the present retrospective cohort study we aim to
describe the epidemiology of LD in a single center in
Israel where both Legionella cultures as well as UAT are
available and routinely performed. We sought to exam-
ine the clinical and microbiological variables associated
with outcome, with a focus on the method of diagnosis.
Methods
Patients and setting
Assaf Harofeh Medical Center is an 850-bed university
affiliated hospital in Central Israel, serving a mainly
urban population of circa 750,000. The Microbiology La-
boratory serves as a national center for clinical diagnosis
of Legionella. All consecutive patients with laboratory
evidence of Legionella infection admitted between Janu-
ary 1, 2006 and December 31, 2012 were retrospectively
identified from the Microbiology Laboratory records,
and patients with diagnosis of pneumonia were included
in the study. The diagnosis of pneumonia was based
on appearance of a new infiltrate on chest radiogram
and at least one of the following: fever ≥37.80C or
hypothermia ≤ 350C, cough with or without sputum pro-
duction, pleuritic chest pain, dyspnea, or abnormal find-
ings on chest auscultation. LD was defined as a case of
pneumonia with supporting laboratory evidence (either a
positive L. pneumophila culture from any source or a
positive UAT for Legionella). Children <18 years and pa-
tients with undetermined disease onset were excluded
from the clinical analyses. All patients with positive cul-
tures were eligible for microbiologic analyses.
We assumed that decisions on specific anti-Legionella
treatment were made by the treating physician when a
positive test result for Legionella was reported. The pri-
mary method of diagnosis was defined as either a posi-
tive UAT test or a positive L. pneumophila culture.
When both were positive in the same patient—the pri-
mary method of diagnosis was determined based on the
order of reported test results. The number of adult pa-
tients with the diagnosis of pneumonia during the study
years was retrieved from the hospital archives using
ICD-9-CM diagnoses codes 481–484 and 486 for de-
nominator calculation.
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Data collection
Detailed data regarding patient demographics, under-
lying diseases, possible exposure, clinical presentation,
clinical course, diagnostic workup, intensive care unit
(ICU) admission, need for intubation and outcome were
retrieved from medical charts and laboratory records.
Underlying conditions and performance status was
assessed according to the Charlson score [19].
Macrolides (roxithromycin 150–300 mg bid or azi-
thromycin 500mg qd), quinolones (ciprofloxacin 400–
500mg bid, levofloxacin 500–750 mg qd or moxifloxacin
400 mg qd) or tetracyclines (doxycycline 100mg bid)
given orally or intravenously were considered appro-
priate antibiotic therapy for LD. Throughout the
study years the recommended empirical institutional
protocols for the treatment of community acquired
pneumonia not requiring intensive ICU admission
consisted of an intravenous third generation cephalo-
sporin (ceftriaxone 1–2g qd) with a macrolide (roxi-
thromycin or azithromycin) or a respiratory quinolone
(levofloxacin or moxifloxacin, usually given orally), or
a respiratory quinolone alone. For patients who were
admitted to ICU the empirical treatment consisted
of an intravenous third generation cephalosporin
(ceftriaxone) with an intravenous macrolide (azithro-
mycin) or a respiratory quinolone (levofloxacin or
moxifloxacin).
Laboratory methods
Respiratory specimens were routinely inoculated on
blood agar, chocolate agar, Sabouraud dextrose agar and
MacConkey agar media and commercial buffered char-
coal yeast extract medium (BCYE) for Legionella. Blood
cultures were processed by the BacT/Alert system (Or-
ganon Teknika, Durham, NC, USA). Growing isolates
were identified as Legionella by Legionella Latex Agglu-
tination Test (Oxoid, Basingstoke, UK), which allows dif-
ferential identification of L. pneumophila serogroup 1
and serogroups 2–14 as well as the detection of seven
other Legionella species which have been implicated in
human disease. Specific identification of serogroups
2–14 was performed using monoclonal antibodies
(m-TECH Inc., Milton, GA, USA). Immunological sub-
grouping was performed for representative strains using
the Dresden Panel of monoclonal antibodies [20].
Urinary antigen testing was performed using a com-
mercial ELISA-based kit (Bartels Legionella Urinary
Antigen ELISA, Trinity Biotech, Bray, Ireland), according
to the manufacturer’s instructions. Equivocal results
were resolved by testing using a second commercial kit
(BinaxNOW Legionella Urinary Antigen EIA, Alere,
Orlando, FL, USA).
Molecular typing was carried out according to the
Sequence-Based Typing (SBT) scheme for Legionella
pneumophila (ESCMID Study Group for Legionella In-
fections, formerly EWGLI) [21, 22]. The allelic profiles
and sequence types (ST) were determined using the
Legionella Sequence Quality Tool [23] as well as the
BioNumerics (Applied Maths, Sint-Martens-Latem,
Belgium) software .
Statistical methods
To study the association between all-cause 30-day mor-
tality (a binary dependent variable) and various factors,
univariate logistic models were initially applied. Signifi-
cant (p ≤ 0.10) non-correlated factors were next in-
cluded in multivariate logistic regression models to
calculate odds ratio (OR) and 95 % confidence interval
(CI).
Kaplan–Meier survival curves and univariate Cox re-
gressions were used to compare time to death (all-cause
mortality within 30 days from admission) between pa-
tients who received appropriate vs. inappropriate therapy
within 2 days of hospital admission and those who were
admitted or not to ICU. SPSS version 21 (SPSS Inc.,
Chicago, Il, USA) was used for all analyses.
Ethical consideration
The study was approved by the local ethical committee
at Assaf Harofeh Medical Center and patient’s anonym-
ity was secured throughout the study
Results and discussion
Patients and outcome
During the study period, 83 patients were identified with
positive Legionella culture (26 patients), positive UAT
test (44 patients) or both (13 patients) (Fig. 1). Five pa-
tients were excluded due to missing charts (n = 3) or
misdiagnosis (n = 2). Seventy eight patients fulfilled the
selection criteria for LD and thus comprised the study
cohort. Five adult patients with undetermined disease
onset and two pediatric patients aged <6 months, who
contracted humidifier-associated pediatric LD (reported
elsewhere [24] ) were excluded from the mortality ana-
lyses. Six of these patients had positive cultures and were
included in the microbiology analyses. Seventy one adult
patients were thus eligible for LD mortality analysis, and
will be referred to as the LD study group. During the
study period 9,015 were discharged from the hospital
with a diagnosis of pneumonia (average of 1,288 per
year).
Diagnosis of LD in the study group was based on posi-
tive culture in 18 patients (25.4 %), positive UAT in 42
patients (59.2 %), and both in 11 patients (15.5 %).
Altogether culture was positive in 29 patients (40.8 %).
According to timing of laboratory reports it was judged
that primary LD diagnosis was based on UAT results in
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50 patients (70.4 %) and on culture results in the
remaining 21 patients (29.6 %).
The characteristics of the patients included in the LD
study group are presented in Table 1. The all-cause 30-
day mortality rates for the LD study group were 15.5 %
overall and 42.9 % in those admitted to ICU. In the uni-
variate analyses (Table 1) high Charlson comorbidity
index (OR = 1.33, 95 % CI 1.00–1.77, p = 0.05), diagnosis
of leukemia (OR = 8.00, 95 % CI 1.63–39.35, p = 0.01),
prior hospitalization within 30 days (OR = 5.14, 95 % CI
1.16–22.82, p = 0.03), and ICU admission (OR=18.00,
95 % CI 3.43-94.44, p=0.001) were positively associated
with all-cause 30-day mortality. Primary diagnosis by
UAT compared to diagnosis by culture (OR = 0.17, 95 %
CI 0.004–0.68, p = 0.01) and administration of appropriate
antibiotic therapy within two hospitalization days com-
pared to delayed therapy (OR = 0.09, 95 % CI 0.002–0.37,
p = 0.001) were negatively associated with mortality.
Four non-correlated variables and age were included
in the first multivariate model (Table 2 multivariate
model 1). Early administration of appropriate antibiotic
therapy within two hospitalization days compared to de-
layed treatment (OR = 0.16, 95 % CI 0.03–0.90, p = 0.04)
and primary diagnosis by UAT compared to cultures
(OR = 0.18, 95 % CI 0.03–0.98, p = 0.05) were found as
independent variables negatively associated with death at
30 days. ICU admission was considered an intermediate
variable and was not included in the initial model.
ICU admission rates were found to be significantly
higher in patients primarily diagnosed by culture (57.1 %)
compared to UAT (18.0 %) (OR = 6.07, 95 % CI 1.97–
18.73, p = 0.002). Notably cultures were submitted for all
21 patients admitted to ICU and for 32 of 50 patients
(64.0 %) who were not. When ICU admission was added
into the multivariate model as a covariate (Table 2 multi-
variate model 2) the primary method of diagnosis was no
longer significant, while early administration of appropri-
ate antibiotic within two hospitalization days remained
significant.
Survival curves for all-cause 30-day mortality compar-
ing patients by ICU admission or by appropriateness of
therapy within the first two days of admission are pre-
sented in Figs. 2 and 3. The hazard ratios according to
the Cox regression analysis were 12.90 (95 % CI 2.78–
59.86, p = 0.001) and 0.13 (95 % CI 0.04–0.46, p = 0.001)
for these two comparisons, respectively.
Microbiologic results
Culture was positive for L. pneumophila in 35 of 78
(44.9 %) of the patients in the LD cohort as follows: L.
pneumophila serogroup 1 in 28 (80.0 %) patients, ser-
ogroup 4 in 2 (5.7 %) patients, serogroup 3 and ser-
ogroup 8 in one (2.9 %) patient, each. The serogroup of
3 isolates could not be determined. Combined with the
positive UAT results, 71 of 78 patients (91.0 %) were
presumably diagnosed as having serogroup 1 infection
(91.5 % of 71 patients in the LD study group). Import-
antly, the majority of positive cultures (23 of 35, 67.5 %)
originated from patients who were intubated.
Genotyping was performed on 30 of 35 (85.7 %) L.
pneumophila isolates. Some of the isolates were included
in a recent report from Israel [18]. The following STs
were found: ST1 (15 cases, 50.0 %), ST40 (4, 13.3 %),
ST42 (2, 6.7 %), ST87 (2, 6.7 %), and ST23, ST338,
ST345, ST1207, ST1351 (one case, each). ST1207 and
ST1351 were novel STs [18], and additional two isolates
Fig. 1 Flow chart depicting patient selection and inclusion in the analyzed groups. Abbreviations: UAT urinary antigen test, LD Legionnaires’ disease
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(6.7 %) were untypeable. The genetic relatedness of the
characterized strains is shown in Fig. 4.
Immunological subtyping was performed for 13 iso-
lates with known STs: all seven ST1 isolates belonged to
OLDA/Oxford, and the two ST40 isolates belonged to
the Allentown subgroup. The other four isolates were
Allentown,ST23; Allentown,T1207, Benidorm,ST42, and
Knoxville,ST345. Thus OLDA/Oxford,ST1 was the most
common phenon responsible for 53.8 % of the character-
ized phenons and 23.3 % of all typed isolates.
Table 1 Univariate logistic analyses, variables associated with all-cause 30-day in-hospital mortality
Parametersa, Alive (N = 60) Dead (N = 11) OR, 95 % CI P-value
Demography
Age, years, mean ± SD 65.7 ± 15.5 74.6 ± 9.5 1.05, 1.0–1.10 0.08
Male sexb 42 (70.0) 8 (72.7) 0.88, 0.21–3.68 0.86
Predisposing conditions
Nonec 7 (11.7) 0 - 1.00
Myocardial infarctionc,d 21 (35.0) 5 (45.5) 1.55, 0.42–5.68 0.51
Congestive heart failurec,d 8 (13.3) 4 (36.4) 3.71, 0.88–15.62 0.07
Chronic pulmonary diseasec,d 13 (21.7) 2 (18.2) 0.08, 0.15–4.19 0.80
Diabetesc,d 17 (28.3) 2 (18.2) 0.56, 0.11–2.87 0.49
Leukemiac,d 4 (6.7) 4 (36.4) 8.0, 1.63–39.35 0.01
Lymphomac,d 3 (5) 2 (18.2) 4.22, 0.62–28.87 0.14
Solid tumorc,d 6 (10) 0 - 0.58
Metastatic cancerc,d 2 (3.3) 1 (9.1) 2.9, 0.24–35.07 0.40
Steroid treatmentc, e 7 (11.7) 3 (27.3) 2.84, 0.61–13.30 0.19
Chemotherapyc, e 7 (11.7) 3 (27.3) 2.84, 0.61–13.30 0.19
Current smokerc 23 (38.3) 2 (18.2) 0.36, 0.07–1.80 0.21
Ever smokedc 35 (58.3) 6 (54.5) 0.86, 0.24–3.12 0.82
Hospitalization within 30 daysc 6 (10) 4 (36.4) 5.14, 1.16–22.82 0.03
Charlson comorbidity index, mean ± SD 2.3 ± 2.1 3.7 ± 2.1 1.33, 1.00–1.77 0.05
Laboratory variables at admission
Oxygen saturation, %, mean ±SD 92.1 ± 5.2 88.3 ± 10.7 0.92, 0.83–1.02 0.12
Neutrophil count < 1.0 x109/Lc 2 (18.2)g 7 (10.0) 2.4, 0.40–14.31 0.34
Lymphocyte count < 1.0 x109/Lc 38 (64.4)g 5 (45.5) 0.46, 0.13–1.69 0.24
Creatinine level, μmol/L, mean ± SD 123.8 ± 70.7 168.0 ± 106.1 1.60, 0.88–2.89 0.12
Bilateral infiltrates on chest X-rayc 14 (23.3) 4 (36.4) 1.88, 0.48–7.36 0.37
Primary diagnosis by positive UATf 14 (23.3) 7 (63.6) 0.17, 0.04–0.68 0.01
Antibiotic therapy & outcome
Appropriate therapy on day +1c 37 (61.7) 3 (27.3) 0.23, 0.06–0.98 0.05
Appropriate therapy on day +2 c 52 (86.7) 4 (36.4) 0.09, 0.02–0.37 0.001
Delay in appropriate therapy administration, days, mean ± SD 0.9 ± 1.8 4.2 ± 5.6 1.34, 1.08–1.67 0.01
Quinolones started on day +1c 17 (28.3) 3 (27.3) 1.13, 0.26–4.80 0.87
Quinolones started on day +2c 23 (38.3) 4 (36.4) 0.92, 0.24–3.49 0.90
ICU admissionc 12 (20.0) 9 (81.8) 18.00, 3.43–94.44 0.001
Invasive ventilation c 10 (16.7) 8 (72.7) 13.33, 3.00–59.19 0.001
Abbreviations: OR odds ratio, CI confidence interval, SD standard deviation, ICU intensive care unit
aNo.(%) unless otherwise stated
bReference category: female sex
cReference category: no
dVariables included in the Charlson comorbidity score
eWithin 30 days preceding hospitalization
fReference category: primary diagnosis by positive culture
gMissing data = 1
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All-cause 30-day in-hospital mortality rate for all 35
patients with positive cultures was 37.1 %. Five of 15 pa-
tients with designated ST1 died (33.3 %). Both patients
with ST87 and both patients with nontypeable isolates
died, as well two of the four patients with ST40 (Fig. 4).
Among the patients included in the LD study group only
29 had positive cultures and 9 have died (31.0 %). ST
was determined for 25 patients, and 11 were assigned
ST1. Mortality rate among patients infected with ST1
Table 2 Logistic regression, multivariate models of variables
associated with all-cause 30-day in-hospital mortality
Parameter OR 95 % CI P-value
Multivariate model 1
Mean age, years 1.05 0.98-1.13 0.18
Hospitalization within 30 daysa 1.48 0.19-11.37 0.71
Charlson comorbidity index 1.20 0.81-1.79 0.36
Primary diagnosis by positive UATb 0.18 0.03-0.98 0.05
Appropriate therapy on day +2a 0.16 0.03-0.90 0.04
Multivariate model 2
Mean age, years 1.06 0.95-1.18 0.31
Hospitalization within 30 daysa 1.93 0.19-19.28 0.58
Charlson comorbidity index 1.37 0.88-2.12 0.16
Primary diagnosis by positive UATb 0.88 0.12-6.81 0.91
Appropriate therapy on day +2a 0.04 0.004-0.55 0.009
ICU admissiona 55.54 2.94-1049.35 0. 007
Abbreviations: OR odds ratio, CI confidence interval, UAT urinary antigen test,
ICU intensive care unit
aReference category: no
bReference category: primary diagnosis by positive culture
Fig. 2 Survival of patients with Legionnaires’ disease as a function of
intensive care unit admission. Legend to Fig. 2: Kaplan-Meier short
survival curve (all-cause 30-day in-hospital mortality) for patients with
Legionnaires' disease who were (red line) or were not (green line)
admitted to the intensive care unit (HR = 12.9, 95 % CI 2.780–59.860,
p= 0.001 by Cox regression). + Sign denotes censored. Abbreviations:
HR Hazard ratio
Fig. 3 Survival of patients with Legionnaires' disease as a function of
appropriate antibiotic therapy. Legend to Fig. 3: Kaplan-Meier short
survival curve (all-cause 30-day in-hospital mortality) for patients
with Legionnaires' disease who received (green line) or did not
receive (red line) appropriate antibiotic therapy within the first two
hospitalization days (HR = 0.134, 95 % CI 0.039–0.460, p = 0.001 by Cox
regression). + Sign denotes censored. Abbreviations: HR Hazard ratio
Fig. 4 Genetic relatedness of the characterized L. pneumophila
isolates and associated mortality. Legend to Fig. 4: Minimum
spanning tree showing the sequence types (ST) of L. pneumophila
strains isolated from 30 patients with Legionnaires' disease. Blue
circles represent serogroup 1 strains and purple circles represent the
non-1 serogroups. ST number is shown inside the circle, and circle
size is proportional to the number of strains assigned to each ST.
Lighter shades of blue and purple denote fatal cases (all-cause 30-day
in-hospital mortality). Line length connecting circles is proportional to
the number of allele difference (in parentheses) between the
defined STs. NT denotes nontypeable
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genotype was 18.2 % compared to 42.9 % for those
infected with non-ST1 genotypes (OR = 0.30, 95 % CI
0.05–1.91, p = 0.23). ICU admission rates among these
patients were 36.4 % and 78.6 %, respectively (OR = 0.16,
95 % CI 0.03–0.92, p = 0.05).
Discussion
We describe a cohort of patients with LD from a single
center where Legionella UAT and cultures from respira-
tory specimens are routinely performed. This unique
setup enabled us to assess the impact of diagnosis by
UAT compared to culture on outcome. We found that
diagnosis by UAT was associated with decreased mortal-
ity at 30 days when compared to diagnosis by a positive
culture. However, when controlling for ICU admission,
this association was no longer present, suggesting that
the severity of the disease and invasive ventilation may
have been confounding factors. Indeed, the majority of
the patients in the LD study group primarily diagnosed
by culture was admitted to ICU and was intubated im-
plying that high quality sputum samples were more
readily achievable in that patient group.
In a large epidemiologic study from the US, Benin et
al. [3] described the impressive trend of decreasing mor-
tality from LD concomitant with the increasing use of
UAT for diagnosis. However, when looking at each sub-
group separately, the mortality trend was significant only
among persons diagnosed by culture, but not among
those diagnosed by UAT. It was argued that UAT may
have selected persons with less severe illness or hastened
the initiation of appropriate antibiotics.
We found that administration of appropriate antibi-
otics within the first two hospitalization days was nega-
tively associated with fatal outcome, even after
controlling for ICU admission. This finding is in agree-
ment with a recent large study of LD from Spain, show-
ing that inappropriate empirical antibiotic therapy was
an independent risk factor for severe outcomes (e.g. ICU
admission or death) [25]. Early coverage of Legionella
has proven beneficial in a recent large prospective study
of combination therapy for moderate to severe commu-
nity acquired pneumonia [26]. This can be achieved by
adherence to the Infectious Diseases Society of America/
American Thoracic Society consensus guidelines for the
empirical therapy of community acquired pneumonia
recommending the administration of combination ther-
apy including a beta-lactam antibiotic plus an agent cov-
ering atypical organisms [27]. Despite the controversy
regarding the added value of an agent covering ‘atypical’
pathogens in the combination regimens [28–33], its role in
patients with LD has not been disputed [34]. Our institu-
tional guidelines recommended combination therapy for
empirical community acquired pneumonia therapy and spe-
cific anti-Legionella coverage for severe pneumonia.
Unfortunately, the compliance with these guidelines was less
then optimal. Only 56.3 % of the patients in the LD study
group received appropriate antibiotic therapy on day 1.
All-cause 30-day in-hospital mortality rates in our LD
study group reached 15.5 %. Comparison to mortality
rates in other studies should be carried out with caution,
taking into account differences in the patient mix, delay
in appropriate antibiotic treatment and the methodology
of outcome reporting. For example, in a recent large
study including 215 hospitalized patients from a single
center in Barcelona the in-hospital fatality rate was 6.1 %
[25]. However, there were several important differences
between the two studies: firstly, in the Spanish study the
mean patients’ age was 58.2 years compared to 67.2
years in our study group. Secondly, patients with im-
munosuppressive conditions were excluded from the
Spanish cohort. Thirdly, positive cultures were reported
in only 22.7 % of the Spanish cohort compared to 40.8 %
in our study group. Lastly, in-hospital fatality rate is not
the same as all-cause 30-day mortality rate. The 2014
ECDC surveillance report [10] found a lower average
case fatality rate of 9 % for cases acquired in the com-
munity and higher rates of 28 % for nosocomial cases. In
addition, the majority of cases were diagnosed by UAT
(79 %) and only 10 % by culture. On the other hand, in a
recent national report from France [35] including 1,192
patients with culture-confirmed LD and a mean age of
59.4 years, the death rate of 18.6 % was closer to the
rates reported in our study.
The proportion of serogroup 1 (80.0 %) among isolates
obtained by culture in our study is similar to the global
rates [10, 36]. The distribution of genotypes, with ST1
(50.1 %) and the OLDA/Oxford,ST1 phenon (23.3 %)
the most frequently encountered isolates in our center,
differed from many European localities. In a study from
England and Wales [37] the leading genotypes from clin-
ical isolates were ST47 (25.7 %) and ST37 (11.4 %), while
ST1 accounted for only 4.8 % of isolates. However, ST1
was the leading genotype among environmental isolates
(19.6 %). In another study from Belgium [38] the leading
genotype among patient with community-acquired legio-
nellosis was ST47, while ST1 was the most frequent iso-
late among nosocomial cases. In a recent French study
the leading genotype was ST23 (19.8 %), while ST1
ranked third (9.1 %) [36]. Notably, in a study from Japan
ST1 was the leading genotype (8.1 %) and OLDA,ST1
the most commonly encountered phenon [39].
Studies examining possible correlation between Le-
gionella genotypes and clinical course or outcome of LD
are scarce. In our study mortality rates among patients
infected with ST1 was somewhat lower compared to the
whole group of patients with positive cultures. Mortality
rates were higher in patients with some other STs (100 %
for STs 87 and nontypeable isolates and 50 % for ST 40),
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but the numbers in each group are too small for any
generalization. A large epidemiologic study from France
involving 1,090 patients and using pulsed field gel elec-
trophoresis as the genotyping tool showed that mortality
rates differed between genotypes, with Paris strain being
most lethal [5]. Notably, the ‘Paris’ strain is in fact ST1
which was the most commonly encountered ST in our
series. In a more recent study from the same group in
France the following death rates were found: 30.9 % for
ST1, 16.3 % for ST23, 13.2 % for ST47 and 18.6 % for all
the other STs [35]. Although these studies suggest that
ST1 is more virulent, however in our study ST1 was not
associated with the highest mortality rates. One possible
explanation is that less virulent strains may be associated
with illness in immunocompromised patients and out-
come in such patients may be grave due to delayed
diagnosis or diminished immunity. Another possible ex-
planation is that ST1 based on the SBT scheme may not
be the same in all geographic localities. Using more
discriminative next generation-based typing [40] in large
epidemiologic studies may help to shed more light on
this issue.
There are several limitations to our study. The study
was of a retrospective nature, and may represent only a
selected group of patients hospitalized with LD. For ex-
ample, since UAT was not performed systematically in
all admitted patients, it is possible that the treating phy-
sicians were more likely to look for LD in patients with
more severe presentations. Such selection bias may re-
sult in higher ICU admissions and mortality rates. In
addition, the study included a single center with a rela-
tively small sample size of patients with positive cultures
and genotype characterization.
Conclusion
The present study confirms the importance of early ad-
ministration of antibiotic therapy for improved outcome
in hospitalized patients with LD. It also demonstrates
the methodological challenges in studies attempting to
assess the impact of the diagnostic strategy, such as
rapid urinary test versus culture, on LD outcome. Diag-
nosis based on UAT may potentially shorten the time to
the diagnosis and thus facilitate faster administration of
appropriate therapy. However, the increasing use of em-
piric combination therapy for pneumonia covering atyp-
ical pathogens may diminish this impact. Diagnosis by
culture is the gold standard and allows characterization
of L. pneumophila isolates. Since culture is more readily
achievable in patients who are intubated, reliance on
culture may introduce a selection bias of sicker patients
with worse outcome.
The study also provides preliminary data regarding the
association of L. pneumophila molecular subtypes and
clinical outcome. In contrast to some recent studies,
ST1 did not stand out as the most virulent strain. These
geographic variations may be further clarified by apply-
ing more refined molecular tools such as next gener-
ation sequencing- based typing schemes.
Abbreviations
CI: confidence interval; HR: hazard ratio; ICU: intensive care unit;
LD: Legionnaires’ disease; OR: odds ratio; SBT: Sequence-Based Typing;
UAT: urinary antigen test.
Competing interests
The authors declare that they have no competing interests.
Authors’ contribution
AL collected all data, analyzed and interpreted the data, drafted the
manuscript and contributed to manuscript revisions. TL was responsible for
the isolation, identification and classical immunologic typing of all Legionella
isolates, and contributed to the manuscript drafting and revisions. JM-G
helped to design the study, coordinated the molecular workup and contrib-
uted to the manuscript drafting and revisions. CP was responsible for con-
structing the models in the statistical analyses, for performing the various
analyses and contributed to the manuscript drafting and revisions. EY carried
out the molecular workup and contributed to the manuscript drafting and
revisions. LV coordinated the molecular workup and contributed to the
manuscript drafting and revisions. MW conceived the study and participated
in its design and coordination, was responsible for data interpretation and
analyses, helped with the manuscript drafting and revisions. All authors read
and approved the final manuscript
Acknowledgments
The authors would like to thank the Respiratory and Vaccine Preventable
Bacteria Reference Unit, Reference Microbiology Services, Public Health
England, London, United Kingdom for typing and analysis of some of the
strains reported in this study.
Author details
1Infectious Diseases Unit, Assaf Harofeh Medical Center, Zerifin 70300, Israel.
2Microbiology Laboratory, Assaf Harofeh Medical Center, Zerifin 70300, Israel.
3National Program for Legionellosis Control and Public Health Services, Israeli
Ministry of Health, 39 Yermiyahu St., 5th Floor, Jerusalem, Israel. 4ESCMID
Study Group for Legionella Infections (ESGLI), Basel, Switzerland. 5Faculty of
Health Sciences, Ben-Gurion University of the Negev. Ben-Gurion Boulevard,
Beer-Sheva, Israel. 6School of Public Health, Epidemiology, Sackler School of
Medicine, Tel Aviv University, POB 39040, Tel Aviv 69978, Israel. 7Molecular
Laboratory, Central Laboratories, Israel Ministry of Health, POB 34410,
Jerusalem 94467, Israel. 8Sackler School of Medicine, Tel Aviv University, POB
39040, Tel Aviv 69978, Israel.
Received: 23 September 2015 Accepted: 22 January 2016
References
1. Den Boer JW, Nijhof J, Friesema I. Risk factors for sporadic community-
acquired Legionnaires’ disease. A 3-year national case-control study. Public
Health. 2006;120:566–71.
2. Carratala J, Garcia-Vidal C. An update on Legionella. Curr Opin Infect Dis.
2010;23:152–7.
3. Benin AL, Benson RF, Besser RE. Trends in legionnaires disease, 1980-1998:
declining mortality and new patterns of diagnosis. Clin Infect Dis.
2002;35:1039–46.
4. Mykietiuk A, Carratala J, Fernandez-Sabe N, Dorca J, Verdaguer R, Manresa F,
et al. Clinical outcomes for hospitalized patients with Legionella pneumonia
in the antigenuria era: the influence of levofloxacin therapy. Clin Infect Dis.
2005;40:794–9.
5. Ginevra C, Duclos A, Vanhems P, Campese C, Forey F, Lina G, et al. Host-related
risk factors and clinical features of community-acquired legionnaires disease
due to the Paris and Lorraine endemic strains, 1998-2007, France. Clin Infect
Dis. 2009;49:184–91.
6. Jacobson KL, Miceli MH, Tarrand JJ, Kontoyiannis DP. Legionella pneumonia
in cancer patients. Medicine (Baltimore). 2008;87:152–9.
Levcovich et al. BMC Infectious Diseases  (2016) 16:75 Page 8 of 9
7. Jespersen S, Sogaard OS, Schonheyder HC, Fine MJ, Ostergaard L. Clinical
features and predictors of mortality in admitted patients with community-
and hospital-acquired legionellosis: a Danish historical cohort study. BMC
Infect Dis. 2010;10:124.
8. Mercante JW, Winchell JM. Current and emerging Legionella diagnostics for
laboratory and outbreak investigations. Clin Microbiol Rev. 2015;28:95–133.
9. Centers for Disease C, Prevention. Legionellosis — United States, 2000-2009.
MMWR Morb Mortal Wkly Rep. 2011;60:1083–6.
10. European Centre for Disease Prevention and Control. Legionnaires’ disease
in Europe, 2012. Stockholm: ECDC; 2014. p. 2014.
11. Cunha BA, Burillo A, Bouza E. Legionnaires’ disease. Lancet. 2015;38:376-85.
12. Phin N, Parry-Ford F, Harrison T, Stagg HR, Zhang N, Kumar K, et al.
Epidemiology and clinical management of Legionnaires’ disease. Lancet
Infect Dis. 2014;14:1011–21.
13. Mentasti M, Fry NK, Afshar B, Palepou-Foxley C, Naik FC, Harrison TG.
Application of Legionella pneumophila-specific quantitative real-time PCR
combined with direct amplification and sequence-based typing in the
diagnosis and epidemiological investigation of Legionnaires’ disease. Eur J
Clin Microbiol Infect Dis. 2012;31:2017–28.
14. Parr A, Whitney EA, Berkelman RL. Legionellosis on the Rise: A Review of
Guidelines for Prevention in the United States. J Public Health Manag Pract.
2015;21:E17–26.
15. European Centre for Disease Prevention and Control. Annual
epidemiological report 2014 –Respiratory tract infections. Stockholm: ECDC;
2014. p. 2014.
16. Lieberman D, Porath A, Schlaeffer F, Lieberman D, Boldur I. Legionella
species community-acquired pneumonia. A review of 56 hospitalized adult
patients. Chest. 1996;109:1243–9.
17. Oren I, Zuckerman T, Avivi I, Finkelstein R, Yigla M, Rowe JM. Nosocomial
outbreak of Legionella pneumophila serogroup 3 pneumonia in a new
bone marrow transplant unit: evaluation, treatment and control. Bone
Marrow Transplant. 2002;30:175–9.
18. Moran-Gilad J, Mentasti M, Lazarovitch T, Huberman Z, Stocki T, Sadik C,
et al. Molecular Epidemiology of Legionnaires’ Disease in Israel. Clin
Microbiol Infect. 2014;20:690-6.
19. Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying
prognostic comorbidity in longitudinal studies: development and validation.
J Chronic Dis. 1987;40:373–83.
20. Helbig JH, Bernander S, Castellani Pastoris M, Etienne J, Gaia V, Lauwers S,
et al. Pan-European study on culture-proven Legionnaires’ disease:
distribution of Legionella pneumophila serogroups and monoclonal
subgroups. Eur J Clin Microbiol Infect Dis. 2002;21:710–6.
21. Ratzow S, Gaia V, Helbig JH, Fry NK, Luck PC. Addition of neuA, the gene
encoding N-acylneuraminate cytidylyl transferase, increases the
discriminatory ability of the consensus sequence-based scheme for
typing Legionella pneumophila serogroup 1 strains. J Clin Microbiol.
2007;45:1965–8.
22. Gaia V, Fry NK, Afshar B, Luck PC, Meugnier H, Etienne J, et al. Consensus
sequence-based scheme for epidemiological typing of clinical and
environmental isolates of Legionella pneumophila. J Clin Microbiol.
2005;43:2047–52.
23. Underwood AP, Bellamy W, Afshar B, Fry NK, Harrison TG. Development of
an online tool for the European Working Group for Legionella Infections
sequence-based typing, including automatic quality assessment and data
submission. In: Cianciotto NP, Abu Kwaik Y, Edelstein PH, Fields BS, Geary
DF, Harrison TG, Joseph C, Ratcliff RM, Stout JE, Swanson MS, editors.
Legionella: state of the art 30 years after its recognition. Washington: ASM
Press; 2006. p. 163–6.
24. Moran-Gilad J, Lazarovitch T, Mentasti M, Harrison T, Weinberger M, Mordish
Y, et al. Humidifier-associated paediatric Legionnaires' disease, Israel,
February 2012. Euro Surveill. 2012;17:20293.
25. Viasus D, Di Yacovo S, Garcia-Vidal C, Verdaguer R, Manresa F, Dorca J, et al.
Community-acquired Legionella pneumophila pneumonia: a single-center
experience with 214 hospitalized sporadic cases over 15 years. Medicine
(Baltimore). 2013;92:51–60.
26. Garin N, Genne D, Carballo S, Chuard C, Eich G, Hugli O, et al. beta-Lactam
monotherapy vs beta-lactam-macrolide combination treatment in
moderately severe community-acquired pneumonia: a randomized
noninferiority trial. JAMA Intern Med. 2014;174:1894–901.
27. Mandell LA, Wunderink RG, Anzueto A, Bartlett JG, Campbell GD, Dean NC,
et al. Infectious Diseases Society of America/American Thoracic Society
consensus guidelines on the management of community-acquired
pneumonia in adults. Clin Infect Dis. 2007;44 Suppl 2:S27–72.
28. Asadi L, Eurich DT, Gamble JM, Minhas-Sandhu JK, Marrie TJ, Majumdar SR.
Guideline adherence and macrolides reduced mortality in outpatients with
pneumonia. Respir Med. 2012;106:451–8.
29. Asadi L, Eurich DT, Gamble JM, Minhas-Sandhu JK, Marrie TJ, Majumdar SR.
Impact of guideline-concordant antibiotics and macrolide/beta-lactam
combinations in 3203 patients hospitalized with pneumonia: prospective
cohort study. Clin Microbiol Infect. 2013;19:257–64.
30. Frei CR, Attridge RT, Mortensen EM, Restrepo MI, Yu Y, Oramasionwu CU,
et al. Guideline-concordant antibiotic use and survival among patients with
community-acquired pneumonia admitted to the intensive care unit. Clin
Ther. 2010;32:293–9.
31. McCabe C, Kirchner C, Zhang H, Daley J, Fisman DN. Guideline-concordant
therapy and reduced mortality and length of stay in adults with
community-acquired pneumonia: playing by the rules. Arch Intern Med.
2009;169:1525–31.
32. Postma DF, van Werkhoven CH, van Elden LJ, Thijsen SF, Hoepelman AI,
Kluytmans JA, et al. Antibiotic treatment strategies for community-acquired
pneumonia in adults. N Engl J Med. 2015;372:1312–23.
33. Lee JS, Fine MJ. The debate on antibiotic therapy for patients hospitalized
for pneumonia: where should we go from here? JAMA Intern Med.
2014;174:1901–3.
34. Eliakim-Raz N, Robenshtok E, Shefet D, Gafter-Gvili A, Vidal L, Paul M, et al.
Empiric antibiotic coverage of atypical pathogens for community-acquired
pneumonia in hospitalized adults. Cochrane Database Syst Rev.
2012;9:CD004418.
35. Cassier P, Campese C, Le Strat Y, Che D, Ginevra C, Etienne J, et al.
Epidemiologic characteristics associated with ST23 clones compared to ST1
and ST47 clones of Legionnaires disease cases in France. New Microbes
New Infect. 2015;3:29–33.
36. Yu VL, Plouffe JF, Pastoris MC, Stout JE, Schousboe M, Widmer A, et al.
Distribution of Legionella species and serogroups isolated by culture in
patients with sporadic community-acquired legionellosis: an international
collaborative survey. J Infect Dis. 2002;186:127–8.
37. Harrison TG, Afshar B, Doshi N, Fry NK, Lee JV. Distribution of Legionella
pneumophila serogroups, monoclonal antibody subgroups and DNA
sequence types in recent clinical and environmental isolates from England
and Wales (2000-2008). Eur J Clin Microbiol Infect Dis. 2009;28:781–91.
38. Vekens E, Soetens O, De Mendonca R, Echahidi F, Roisin S, Deplano A, et al.
Sequence-based typing of Legionella pneumophila serogroup 1 clinical
isolates from Belgium between 2000 and 2010. Euro Surveill. 2012;17:20302.
39. Amemura-Maekawa J, Kura F, Helbig JH, Chang B, Kaneko A, Watanabe Y,
et al. Characterization of Legionella pneumophila isolates from patients in
Japan according to serogroups, monoclonal antibody subgroups and
sequence types. J Med Microbiol. 2010;59:653–9.
40. Moran-Gilad J, Prior K, Yakunin E, Harrison TG, Underwood A, Lazarovitch T,
et al. Design and application of a core genome multilocus sequence typing
scheme for investigation of Legionnaires' disease incidents. Euro Surveill.
2015;20.
•  We accept pre-submission inquiries 
•  Our selector tool helps you to find the most relevant journal
•  We provide round the clock customer support 
•  Convenient online submission
•  Thorough peer review
•  Inclusion in PubMed and all major indexing services 
•  Maximum visibility for your research
Submit your manuscript at
www.biomedcentral.com/submit
Submit your next manuscript to BioMed Central 
and we will help you at every step:
Levcovich et al. BMC Infectious Diseases  (2016) 16:75 Page 9 of 9
